Diabetes, Obesity and Metabolism
Издатель: Wiley · ISSN 14628902 · 82 статей
- Real‐World Effectiveness of SGLT2i on Incident Kidney Outcomes in Patients With Type 2 Diabetes and Normoalbuminuria—A Territory‐Wide Retrospective Study
- Testosterone Added to Incretin Therapy in Men With Overweight or Obesity: A Systematic Review of Body Composition Evidence and Gaps
- Effects of a Prebiotic Functional Soda on Gastrointestinal Symptoms in Adults Receiving GLP‐1–Based Therapy for Weight Management: A Randomized Controlled Pilot Trial
- Metformin in Advanced Chronic Kidney Disease: A Systematic Review and Meta‐Analysis
- Beyond Plasma Exposure: Interpreting the Pharmacodynamic Signals of RGH‐706 for Rational Dose Selection
- Naltrexone/Bupropion Significantly Improves Overweight‐ and Obesity‐Related Estimated Renal Hyperfiltration: A Post Hoc Pooled Analysis
- Sensitive First Line Screening for Early‐Stage Type 1 Diabetes on Dried Blood Spots
-
Early Continuous Glucose Monitoring to Lower the Risk of Gestational Diabetes Mellitus in Women With Pre‐Pregnancy Obesity: Protocol for the Multicentre Randomised Controlled Trial (GLOW)
ABSTRACT Aims Pre‐pregnancy obesity substantially increases the risk of gestational diabetes mellitus ( GDM ), yet preventive strategies before routine GDM screening remain limited. The Glucose monitoring to Lower risk of GDM in Obese...
-
Insulin Secretion Modelling to Characterize Post‐Bariatric Hypoglycaemia After Roux‐en‐Y Gastric Bypass
ABSTRACT Aim Roux‐en‐Y Gastric Bypass (RYGB) is an effective treatment for obesity and Type 2 diabetes. Some individuals develop postprandial hypoglycaemia, termed post‐bariatric hypoglycaemia (PBH). PBH is associated with marked...
- What Would Show That Strength Is Preserved During Semaglutide Weight Loss?
-
Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States
ABSTRACT Aims Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction‐associated steatohepatitis but have not been tested together. We examined recorded incretin exposure among resmetirom initiators and the frequency...
-
Impact of Different Meal Types and Macronutrients on Circulating FGF21 and Appetite in Humans: A Systematic Review of Randomized Trials
ABSTRACT Introduction and Aim Fibroblast growth factor 21 (FGF21) is potentially involved in macronutrient specific appetite regulation by increasing preference for protein and suppressing preference for sugar and alcohol. The aim of...
-
Association of Continuous Glucose Monitoring‐Based Nocturnal Glucose Patterns With Microvascular Complications in Patients With Type 2 Diabetes
ABSTRACT Aims To characterize metabolic heterogeneity in Type 2 diabetes mellitus (T2DM), we used continuous glucose monitoring (CGM) data to identify nocturnal glucose patterns and examine their associations with clinical and metabolic...
-
Endoscopic Ultrasound‐Guided Bypass Reversal for Postprandial Reactive Hypoglycaemia After Roux‐En‐Y Gastric Bypass Surgery: Results of a Prospective Pilot Study
ABSTRACT Background and Aim Postprandial reactive hypoglycaemia syndrome (PRHS) is an increasingly recognized complication after Roux‐en‐Y gastric bypass (RYGB) surgery. We investigated whether endoscopic ultrasound (EUS)‐guided bypass...
-
GLP‐1(9‐37) Improves Left Ventricular Function in a Murine Model of Cardiac Pressure Overload by Promoting Mitochondrial Biogenesis
ABSTRACT Aim Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone that is released in response to nutrient intake and inflammation. Its active form, GLP‐1(7‐37), binds to the GLP‐1 receptor (GLP‐1R), but GLP‐1 is rapidly degraded by...
- Comparison of Sensor Accuracy for Three Different CGM‐Systems Using Either Displayed or Auto‐Logged Values in Individuals With Type 1 Diabetes Mellitus
-
Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial
ABSTRACT Aims To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. Materials and Methods In this multicentre, randomised,...
-
MCP‐1 as a Biomarker of Vascular Function
ABSTRACT Background Endothelial dysfunction and arterial stiffness have been shown to be associated with cardiovascular disease (CVD) outcomes but assessment of these is not straightforward. CVD risk in diabetes shows heterogeneity and...
-
Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE
ABSTRACT Background Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) provide kidney protection in patients with diabetic kidney disease (DKD). There is limited knowledge about the mechanisms by which they protect the kidney. We...
-
A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP‐1 Agonists in the United Kingdom
ABSTRACT Aims We previously showed that FreeStyle Libre (FSL) real‐time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self‐monitoring of blood glucose (SMBG)...
-
Pre‐Treatment Biomarkers Associated With Remission of Type 2 Diabetes in Response to Short‐Term Insulin‐Based Therapy
ABSTRACT Aims Short‐term insulin‐based therapy can induce remission of Type 2 diabetes (T2DM) in some but not all patients. The underlying determinant of whether remission can be achieved is beta‐cell function, but its assessment...
- Societal and Economic Burden of Type 1 Diabetes Across Disease Stages in Italy
-
Polygenic Risk for Type 2 Diabetes, Multiple Risk Factor Control and Cardiovascular and Non‐Cardiovascular Mortality
ABSTRACT Aims To examine the independent and joint associations of Type 2 diabetes mellitus (T2DM) genetic susceptibility and control of multiple modifiable cardiovascular risk factors with all‐cause and cause‐specific mortality....
-
Diurnal Patterns of Accelerometer‐Measured Physical Activity, Genetic Risk and Incident Obesity: A Cohort Study of 58 877 Participants
ABSTRACT Aims To examine the associations of diurnal physical activity patterns with incident obesity and whether these associations vary by genetic susceptibility. Materials and Methods This prospective study included 58 877 UK Biobank...
- Ursodeoxycholic Acid Prophylaxis During Incretin‐Based Obesity Management: An Evidence Gap Worth Addressing?
- Validation of the Progression Likelihood Score (PLS) for Stratifying Progression Rates in Early‐Stage Type 1 Diabetes
-
Association Between Orforglipron and Blood Pressure in Adults With Obesity With or Without Type 2 Diabetes: Post Hoc Analyses From ATTAIN‐1 and ATTAIN‐2 Trials
ABSTRACT Introduction This post hoc analysis assessed the association between orforglipron and blood pressure in adults with obesity or overweight without (ATTAIN‐1) and with Type 2 diabetes (T2D; ATTAIN‐2). Methods This study included...
-
Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation
ABSTRACT Aims Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP‐1 and...
- Daily Steps and Heart Rate After Semaglutide or Tirzepatide Initiation: An Apple HealthKit Cohort in All of Us
-
Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non‐Remitters
ABSTRACT Aims Metabolic bariatric surgery (MBS), for example, Roux‐en‐Y gastric bypass (RYGB) can lead to diabetes remission. However, this crude dichotomous outcome fails to fully capture post‐operative improvements in glycaemia and...